{"url_path":"/sec/gctk/8-k/2026-07-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1506983/0001493152-26-033393-index.html","accession_number":"0001493152-26-033393","cik":"0001506983","ticker":"GCTK","issuer_name":"Glucotrack, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506983/0001493152-26-033393-index.html","primary_entity_key":"0001506983","primary_entity_name":"Glucotrack, Inc."},"word_count":405,"has_tables":true,"body_markdown":"** **\n\n**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(a)\nFinancial Statements of Businesses or Funds Acquired\n\n \n\nThe\nAcquiror will file the financial statements of the Company required by Item 9.01(a) as an amendment to this Current Report on Form 8-K\nno later than 71 calendar days after the required filing for this Current Report on Form 8-K.\n\n \n\n(b)\nPro Forma Financial Information\n\n \n\nThe\nAcquiror will file the pro forma financial information required by Item 9.01(b) as an amendment to this Current Report on Form 8-K no\nlater than 71 calendar days after the required filing for this Current Report on Form 8-K.\n\n \n\n \n\n \n\n \n\n(d)\nExhibits\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n2.1*\n \n[Agreement\nand Plan of Merger, dated July 14, 2026, by and among Glucotrack, Inc., Glucotrack Merger Sub, Inc., Lokahi Therapeutics,\nInc., Glucotrack Technologies Inc., and Paul V. Goode.](ex2-1.htm)\n\n3.1\n \n[Certificate of Designation of Series A Convertible Preferred Stock, as filed with the Delaware Secretary of State on July 9, 2026](ex3-1.htm)\n\n3.2\n \n[Amended and Restated Certificate of Designation of Series A Convertible Preferred Stock, as filed with the Delaware Secretary of State on July 14, 2026](ex3-2.htm)\n\n4.1\n \n[Form of Senior Secured Promissory Note, dated July 14, 2026](ex4-1.htm)\n\n4.2\n \n[Form of Warrant, dated July 14, 2026](ex4-2.htm)\n\n4.3\n \n[Commitment Warrant, dated July 14, 2026](ex4-3.htm)\n\n10.1*\n \n[Form of Securities Purchase Agreement, dated July 14, 2026, by and between Glucotrack, Inc. and the investors party thereto](ex10-1.htm)\n\n10.2\n \n[Security Agreement, dated July 14, 2026, by and between Glucotrack, Inc. and White Lion Capital LLC, as collateral agent](ex10-2.htm)\n\n10.3\n \n[Form of Voting Support Agreement, dated July 14, 2026, by and between Glucotrack, Inc. and certain stockholders](ex10-3.htm)\n\n10.4\n \n[Common Stock Purchase Agreement, dated July 14, 2026, by and between Glucotrack, Inc. and White Lion Capital LLC](ex10-4.htm)\n\n10.5\n \n[Registration Rights Agreement, dated July 14, 2026, by and between Glucotrack, Inc. and White Lion Capital LLC](ex10-5.htm)\n\n99.1\n \n[Press Release, dated July 14, 2026](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the inline XBRL document)\n\n \n\n*\nThe\nschedules to this Exhibit have been omitted in accordance with Item 601(b)(2) of Regulation S-K. The Registrant agrees to furnish\nsupplementally to the SEC a copy of all omitted exhibits and schedules upon its request.\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \nGlucotrack,\nInc.\n\n \n \n\nDate:\nJuly 15, 2026\nBy:\n\n*/s/\nErik Emerson*\n\n \nName:\n\nErik\nEmerson\n\n \nTitle:\nChief\nExecutive Officer"}